<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="LINZESS">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  EXCERPT:   Most common adverse reactions (&gt;=2%) reported in IBS-C or CIC patients are: diarrhea, abdominal pain, flatulence and abdominal distension. (  6.1  )

   To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  

 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

 Exposure in clinical development included approximately 2570, 2040, and 1220 patients with either IBS-C or CIC treated with LINZESS for 6 months or longer, 1 year or longer, and 18 months or longer, respectively (not mutually exclusive).

 Demographic characteristics were comparable between treatment groups in all studies  [see Clinical Studies (  14  )]  .

     Irritable Bowel Syndrome with Constipation (IBS-C)  

     Most Common Adverse Reactions  

 The data described below reflect exposure to LINZESS in the two placebo-controlled clinical trials involving 1605 adult patients with IBS-C (Trials 1 and 2). Patients were randomized to receive placebo or 290 mcg LINZESS once daily on an empty stomach for up to 26 weeks.  Table 1  provides the incidence of adverse reactions reported in at least 2% of IBS-C patients in the LINZESS treatment group and at an incidence that was greater than in the placebo group.

 Table 1: Most Common Adverse Reactionsa in Two Placebo-Controlled Trials (1 and 2) in Patients with IBS-C 
  a: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo    
  b: "Abdominal pain" term includes abdominal pain, upper abdominal pain, and lower abdominal pain.    
  
   Adverse Reactions                               LINZESS    290 mcg    [N=807]    %      Placebo    [N=798]    %     
   Gastrointestinal       Diarrhea     Abdominal pain  b       Flatulence     Abdominal distension  20742                         3521                        
   Infections and Infestations       Viral Gastroenteritis  3                             1                           
   Nervous System Disorders       Headache       4                             3                           
             Diarrhea  
 

 Diarrhea was the most commonly reported adverse reaction of the LINZESS-treated patients in the pooled IBS-C pivotal placebo-controlled trials. In these trials, 20% of LINZESS-treated patients reported diarrhea compared to 3% of placebo-treated patients. Severe diarrhea was reported in 2% of the LINZESS-treated patients versus less than 1% of the placebo-treated patients, and 5% of LINZESS-treated patients discontinued due to diarrhea vs less than 1% of placebo-treated patients. The majority of reported cases of diarrhea started within the first 2 weeks of LINZESS treatment  [see Warnings and Precautions (  5.2  )]  .

     Adverse Reactions Leading to Discontinuation  

 In placebo-controlled trials in patients with IBS-C, 9% of patients treated with LINZESS and 3% of patients treated with placebo discontinued prematurely due to adverse reactions. In the LINZESS treatment group, the most common reasons for discontinuation due to adverse reactions were diarrhea (5%) and abdominal pain (1%). In comparison, less than 1% of patients in the placebo group withdrew due to diarrhea or abdominal pain.

     Adverse Reactions Leading to Dose Reductions  

 In the open-label, long-term trials, 2147 patients with IBS-C received 290 mcg of LINZESS daily for up to 18 months. In these trials, 29% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were diarrhea or other GI adverse reactions.

     Less Common Adverse Reactions  

 Defecation urgency, fecal incontinence, vomiting, and gastroesophagal reflux disease were reported in &lt;2% of patients in the LINZESS treatment group and at an incidence greater than in the placebo treatment group.

     Chronic Idiopathic Constipation (CIC)  

     Most Common Adverse Reactions  

 The data described below reflect exposure to LINZESS in the two double-blind placebo-controlled clinical trials of 1275 adult patients with CIC (Trials 3 and 4). Patients were randomized to receive placebo or 145 mcg LINZESS or 290 mcg LINZESS once daily on an empty stomach, for at least 12 weeks.  Table 2  provides the incidence of adverse reactions reported in at least 2% of CIC patients in the 145 mcg LINZESS treatment group and at an incidence that was greater than in the placebo treatment group.

 Table 2: Most Common Adverse Reactionsa in the Two Placebo-controlled Trials (3 and 4) in Patients with CIC 
  a: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo    
  b: "Abdominal pain" term includes abdominal pain, upper abdominal pain, and lower abdominal pain.    
  
   Adverse Reactions                                             LINZESS    145 mcg    [N=430]    %      Placebo    [N=423]    %     
   Gastrointestinal       Diarrhea     Abdominal pain  b       Flatulence     Abdominal distension  16763                 5652                  
   Infections and Infestations       Upper respiratory tract infection     Sinusitis  53                    42                    
         The safety of a 72 mcg dose was evaluated in an additional placebo-controlled trial in which 1223 patients were randomized to LINZESS 72 mcg, 145 mcg, or placebo once daily for 12 weeks (Trial 5).
 

 In Trial 5, adverse reactions that occurred at a frequency of &gt;= 2% in LINZESS-treated patients (n=411 in each LINZESS 72 mcg and 145 mcg group) and at a higher rate than placebo (n=401) were:

 *  Diarrhea (LINZESS 72 mcg 19%; LINZESS 145 mcg 22%; placebo 7%) 
 *  Abdominal distension (LINZESS 72 mcg 2%; LINZESS 145 mcg 1%; placebo &lt; 1%) 
        Diarrhea  
 

 This section summarizes information from Trials 3 and 4 (pooled) and Trial 5 regarding diarrhea, the most commonly reported adverse reaction reported in LINZESS-treated patients in CIC placebo-controlled studies.

 In all trials, the majority of reported cases of diarrhea started within the first 2 weeks of LINZESS treatment.

 Severe diarrhea was reported in less than 1% of the 72 mcg LINZESS-treated patients (Trial 5), in 2% of the 145 mcg LINZESS-treated patients (Trials 3 and 4; Trial 5), and less than 1% of the placebo-treated patients (Trials 3, 4, and 5)  [see Warnings and Precautions (  5.2  )]  .

     Adverse Reactions Leading to Discontinuation  

 In placebo-controlled trials in patients with CIC, 3% of patients treated with 72 mcg (Trial 5) and between 5% (Trial 5) and 8% (Trials 3 and 4) of patients treated with 145 mcg of LINZESS discontinued prematurely due to adverse reactions compared to between less than 1% (Trial 5) and 4% (Trials 3 and 4) of patients treated with placebo.

 In patients treated with 72 mcg LINZESS the most common reason for discontinuation due to adverse reactions was diarrhea (2% in Trial 5) and in patients treated with 145 mcg LINZESS, the most common reasons for discontinuation due to adverse reactions were diarrhea (3% in Trial 5 and 5% in Trials 3 and 4) and abdominal pain (1% in Trials 3 and 4). In comparison, less than 1% of patients in the placebo group withdrew due to diarrhea or abdominal pain (Trials 3 and 4; Trial 5).

     Adverse Reactions Leading to Dose Reductions  

 In the open-label, long-term trials, 1129 patients with CIC received 290 mcg of LINZESS daily for up to 18 months. In these trials, 27% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were diarrhea or other GI adverse reactions.

     Less Common Adverse Reactions  

 Defecation urgency, fecal incontinence, dyspepsia, and viral gastroenteritis, were reported in less than 2% of patients in the LINZESS treatment group and at an incidence greater than placebo treatment group.

   6.2 Postmarketing Experience

  The following adverse reactions have been identified during post approval use of LINZESS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

 Hematochezia, rectal hemorrhage, nausea, and allergic reactions, urticaria or hives.

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

  WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS



    *  LINZESS is contraindicated in patients less than 6 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration [see Contraindications (4), Use in Specific Populations (8.4)]. 
 *  Avoid use of LINZESS in patients 6 years to less than 18 years of age [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)]. 
 *  The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age [see Use in Specific Populations (8.4)]. 
      EXCERPT:     WARNING:  RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS  
 

   See full prescribing information for complete boxed warning.  

 *  LINZESS is contraindicated in patients less than 6 years of age; in neonatal mice, linaclotide caused deaths due to dehydration. (4, 8.4) 
 *  Avoid use of LINZESS in patients 6 years to less than 18 years of age. (5.1, 8.4) 
 *  The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age (8.4). 
    

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *  Diarrhea: Patients may experience severe diarrhea. If severe diarrhea occurs,suspend dosing and rehydrate the patient. (  5.2  ) 
    
 

   5.1 Risk of Serious Dehydration in Pediatric Patients

  LINZESS is contraindicated in patients less than 6 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established. In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.

 Avoid use of LINZESS in pediatric patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of LINZESS in pediatric patients 6 years to less than 18 years of age [see Contraindications (  4  ), Warnings and Precautions (  5.2  ), Use in Specific Populations (  8.4  )]  .

    5.2 Diarrhea

     Diarrhea was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar between the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in &lt;1% of 72 mcg LINZESS-treated CIC patients [see Adverse Reactions (  6.1  )]  .

    In post-marketing experience, severe diarrhea associated with dizziness, syncope, hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or intravenous fluid administration have been reported in patients treated with LINZESS.

    If severe diarrhea occurs, suspend dosing and rehydrate the patient.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="300" name="excerpt" section="S1" start="24" />
    <IgnoredRegion len="150" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="60" name="heading" section="S2" start="83" />
    <IgnoredRegion len="53" name="heading" section="S3" start="190" />
    <IgnoredRegion len="30" name="heading" section="S1" start="328" />
    <IgnoredRegion len="496" name="excerpt" section="S2" start="738" />
    <IgnoredRegion len="12" name="heading" section="S3" start="1286" />
    <IgnoredRegion len="28" name="heading" section="S1" start="8088" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M1" len="5" reason="indication" section="S1" start="1223" type="Not_AE_Candidate">
      <Normalization meddra_llt="IBS" meddra_llt_id="10021192" meddra_pt="Irritable bowel syndrome" meddra_pt_id="10023003" />
    </Mention>
    <Mention id="M18" len="14" reason="from_drug_use" section="S1" start="1769" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M19" len="14" reason="from_drug_use" section="S1" start="1799" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M20" len="20" reason="from_drug_use" section="S1" start="1815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M21" len="20" reason="from_drug_use" section="S1" start="1841" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal pain lower" meddra_llt_id="10000084" meddra_pt="Abdominal pain lower" meddra_pt_id="10000084" />
    </Mention>
    <Mention id="M9" len="16" reason="general_term" section="S1" start="1993" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M22" len="8" reason="from_drug_use" section="S1" start="2016" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M23" len="14" reason="from_drug_use" section="S1" start="2029" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M24" len="10" reason="from_drug_use" section="S1" start="2053" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M25" len="20" reason="from_drug_use" section="S1" start="2068" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal distension" meddra_llt_id="10000060" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M10" len="27" reason="general_term" section="S1" start="2152" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M65" len="21" reason="from_drug_use" section="S1" start="2186" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis viral" meddra_llt_id="10017918" meddra_pt="Gastroenteritis viral" meddra_pt_id="10017918" />
    </Mention>
    <Mention id="M11" len="24" reason="general_term" section="S1" start="2271" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M26" len="8" reason="from_drug_use" section="S1" start="2302" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M27" len="8" reason="from_drug_use" section="S1" start="2404" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M2" len="5" reason="indication" section="S1" start="2507" type="Not_AE_Candidate">
      <Normalization meddra_llt="IBS" meddra_llt_id="10021192" meddra_pt="Irritable bowel syndrome" meddra_pt_id="10023003" />
    </Mention>
    <Mention id="M28" len="8" reason="from_drug_use" section="S1" start="2606" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M29" len="8" reason="from_drug_use" section="S1" start="2666" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M30" len="8" reason="from_drug_use" section="S1" start="2834" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M31" len="8" reason="from_drug_use" section="S1" start="2922" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M3" len="5" reason="indication" section="S1" start="3131" type="Not_AE_Candidate">
      <Normalization meddra_llt="IBS" meddra_llt_id="10021192" meddra_pt="Irritable bowel syndrome" meddra_pt_id="10023003" />
    </Mention>
    <Mention id="M32" len="8" reason="from_drug_use" section="S1" start="3371" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M33" len="14" reason="from_drug_use" section="S1" start="3389" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M12" len="8" reason="AE_only_as_instruction" section="S1" start="3487" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M13" len="14" reason="AE_only_as_instruction" section="S1" start="3499" type="NonOSE_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M4" len="5" reason="indication" section="S1" start="3626" type="Not_AE_Candidate">
      <Normalization meddra_llt="IBS" meddra_llt_id="10021192" meddra_pt="Irritable bowel syndrome" meddra_pt_id="10023003" />
    </Mention>
    <Mention id="M34" len="8" reason="from_drug_use" section="S1" start="3815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M66" len="20" reason="from_drug_use" section="S1" start="3833" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M35" len="18" reason="from_drug_use" section="S1" start="3895" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Defecation urgency" meddra_llt_id="10012114" meddra_pt="Defaecation urgency" meddra_pt_id="10012110" />
    </Mention>
    <Mention id="M36" len="18" reason="from_drug_use" section="S1" start="3915" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incontinence fecal" meddra_llt_id="10021640" meddra_pt="Anal incontinence" meddra_pt_id="10077605" />
    </Mention>
    <Mention id="M37" len="8" reason="from_drug_use" section="S1" start="3935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M38" len="30" reason="from_drug_use" section="S1" start="3949" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroesophageal reflux disease" meddra_llt_id="10066874" meddra_pt="Gastrooesophageal reflux disease" meddra_pt_id="10017885" />
    </Mention>
    <Mention id="M5" len="3" reason="indication" section="S1" start="4335" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic idiopathic constipation" meddra_llt_id="10072118" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M39" len="14" reason="from_drug_use" section="S1" start="4920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M40" len="14" reason="from_drug_use" section="S1" start="4950" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M41" len="20" reason="from_drug_use" section="S1" start="4966" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M42" len="20" reason="from_drug_use" section="S1" start="4992" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal pain lower" meddra_llt_id="10000084" meddra_pt="Abdominal pain lower" meddra_pt_id="10000084" />
    </Mention>
    <Mention id="M14" len="16" reason="general_term" section="S1" start="5158" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M43" len="8" reason="from_drug_use" section="S1" start="5181" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M44" len="14" reason="from_drug_use" section="S1" start="5194" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M45" len="10" reason="from_drug_use" section="S1" start="5218" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M46" len="20" reason="from_drug_use" section="S1" start="5233" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal distension" meddra_llt_id="10000060" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M15" len="27" reason="general_term" section="S1" start="5303" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M47" len="33" reason="from_drug_use" section="S1" start="5337" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M67" len="9" reason="from_drug_use" section="S1" start="5375" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M48" len="8" reason="from_drug_use" section="S1" start="5839" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M49" len="20" reason="from_drug_use" section="S1" start="5907" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Abdominal distension" meddra_llt_id="10000060" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Mention>
    <Mention id="M50" len="8" reason="from_drug_use" section="S1" start="5991" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M68" len="8" reason="from_drug_use" section="S1" start="6093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M6" len="3" reason="indication" section="S1" start="6187" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic idiopathic constipation" meddra_llt_id="10072118" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M51" len="8" reason="from_drug_use" section="S1" start="6270" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M52" len="8" reason="from_drug_use" section="S1" start="6343" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M7" len="3" reason="indication" section="S1" start="6720" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic idiopathic constipation" meddra_llt_id="10072118" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M53" len="8" reason="from_drug_use" section="S1" start="7128" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M54" len="8" reason="from_drug_use" section="S1" start="7273" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M55" len="14" reason="from_drug_use" section="S1" start="7327" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M16" len="8" reason="AE_only_as_instruction" section="S1" start="7443" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M17" len="14" reason="AE_only_as_instruction" section="S1" start="7455" type="NonOSE_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M8" len="3" reason="indication" section="S1" start="7608" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic idiopathic constipation" meddra_llt_id="10072118" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M69" len="8" reason="from_drug_use" section="S1" start="7795" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M70" len="20" reason="from_drug_use" section="S1" start="7813" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M56" len="18" reason="from_drug_use" section="S1" start="7875" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Defecation urgency" meddra_llt_id="10012114" meddra_pt="Defaecation urgency" meddra_pt_id="10012110" />
    </Mention>
    <Mention id="M57" len="18" reason="from_drug_use" section="S1" start="7895" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incontinence fecal" meddra_llt_id="10021640" meddra_pt="Anal incontinence" meddra_pt_id="10077605" />
    </Mention>
    <Mention id="M58" len="9" reason="from_drug_use" section="S1" start="7915" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M59" len="21" reason="from_drug_use" section="S1" start="7930" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis viral" meddra_llt_id="10017918" meddra_pt="Gastroenteritis viral" meddra_pt_id="10017918" />
    </Mention>
    <Mention id="M60" len="12" reason="from_drug_use" section="S1" start="8414" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematochezia" meddra_llt_id="10060544" meddra_pt="Haematochezia" meddra_pt_id="10018836" />
    </Mention>
    <Mention id="M61" len="17" reason="from_drug_use" section="S1" start="8428" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage rectal" meddra_llt_id="10019583" meddra_pt="Rectal haemorrhage" meddra_pt_id="10038063" />
    </Mention>
    <Mention id="M62" len="6" reason="from_drug_use" section="S1" start="8447" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M63" len="18" reason="from_drug_use" section="S1" start="8459" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Allergic reaction to analgesics" meddra_llt_id="10072246" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M64" len="9" reason="from_drug_use" section="S1" start="8479" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M71" len="5" reason="from_drug_use" section="S1" start="8492" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hives" meddra_llt_id="10020197" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M72" len="6" reason="general_term" section="S2" start="344" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M73" len="11" reason="AE_animal" section="S2" start="358" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M79" len="25" reason="AE_animal" section="S3" start="500" type="NonOSE_AE">
      <Normalization meddra_llt="Drug effect increased" meddra_llt_id="10013683" meddra_pt="Drug effect increased" meddra_pt_id="10013683" />
    </Mention>
    <Mention id="M80" len="9" reason="general_term" section="S3" start="572" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M76" len="11" reason="AE_animal" section="S3" start="615" type="NonOSE_AE">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M81" len="8" reason="AE_only_as_instruction" section="S3" start="786" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M77" len="6" reason="general_term" section="S3" start="943" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M78" len="6" reason="general_term" section="S3" start="984" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M89" len="8" reason="from_drug_use" section="S3" start="1305" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M90" len="8" reason="from_drug_use" section="S3" start="1464" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M74" len="5" reason="indication" section="S3" start="1497" type="Not_AE_Candidate">
      <Normalization meddra_llt="IBS" meddra_llt_id="10021192" meddra_pt="Irritable bowel syndrome" meddra_pt_id="10023003" />
    </Mention>
    <Mention id="M75" len="3" reason="indication" section="S3" start="1507" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic idiopathic constipation" meddra_llt_id="10072118" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M91" len="8" reason="from_drug_use" section="S3" start="1531" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M92" len="8" reason="from_drug_use" section="S3" start="1737" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M82" len="9" reason="manifestation_or_complication" section="S3" start="1762" type="NonOSE_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M83" len="7" reason="manifestation_or_complication" section="S3" start="1773" type="NonOSE_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M84" len="11" reason="manifestation_or_complication" section="S3" start="1782" type="NonOSE_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M86" len="25" reason="manifestation_or_complication" section="S3" start="1798" type="NonOSE_AE">
      <Normalization meddra_llt="Electrolyte abnormality" meddra_llt_id="10014410" meddra_pt="Electrolyte imbalance" meddra_pt_id="10014418" />
      <Normalization meddra_pt="Blood electrolytes abnormal" meddra_pt_id="10061014" />
    </Mention>
    <Mention id="M87" len="11" reason="manifestation_or_complication" section="S3" start="1825" type="NonOSE_AE">
      <Normalization meddra_llt="Hypokalemia" meddra_llt_id="10021018" meddra_pt="Hypokalaemia" meddra_pt_id="10021015" />
      <Normalization meddra_pt="Blood potassium decreased" meddra_pt_id="10005724" />
    </Mention>
    <Mention id="M88" len="12" reason="manifestation_or_complication" section="S3" start="1841" type="NonOSE_AE">
      <Normalization meddra_llt="Hyponatremia" meddra_llt_id="10021038" meddra_pt="Hyponatraemia" meddra_pt_id="10021036" />
    </Mention>
    <Mention id="M85" len="8" reason="AE_only_as_instruction" section="S3" start="1985" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
  </Mentions>
</GoldLabel>